{"id":34531,"date":"2018-06-25T12:00:00","date_gmt":"2018-06-25T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/"},"modified":"2018-06-25T12:00:00","modified_gmt":"2018-06-25T12:00:00","slug":"delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/","title":{"rendered":"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--2785 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h3>Nouvelles cibles dans la prise en charge de la rhinite allergique<\/h3>\n<p>La rhinite allergique (RA) reste sous-diagnostiqu\u00e9e, sous-estim\u00e9e et sous-trait\u00e9e. Un \u00e9l\u00e9ment cl\u00e9 pour comprendre le paysage de la RA a \u00e9t\u00e9 la prise de conscience d\u2019un d\u00e9calage important entre la mani\u00e8re dont les m\u00e9decins demandent aux patients de g\u00e9rer leur maladie et ce que ces derniers font dans la vie r\u00e9elle. Les donn\u00e9es de l\u2019<i>Allergy Diary<\/i> (d\u00e9velopp\u00e9 par MACVIA ARIA) ont montr\u00e9 que les patients souffrant de RA prennent leurs m\u00e9dicaments au besoin, changent rapidement de traitement, pr\u00e9sentent souvent un contr\u00f4le m\u00e9diocre, utilisent des th\u00e9rapies multiples et arr\u00eatent le traitement lorsque les sympt\u00f4mes sont contr\u00f4l\u00e9s. Un meilleur contr\u00f4le de la RA pourrait \u00eatre atteint en utilisant un traitement ayant un d\u00e9lai d\u2019action rapide et ciblant efficacement les sympt\u00f4mes de perc\u00e9e. En effet, les patients citent le soulagement complet des sympt\u00f4mes, l\u2019absence de sympt\u00f4mes de perc\u00e9e, la rapidit\u00e9 d\u2019action, la s\u00e9curit\u00e9 et l\u2019utilisation \u00ab au besoin \u00bb comme cibles cl\u00e9s pour les nouveaux sprays nasaux. Le MP-AzeFlu associe l\u2019az\u00e9lastine intranasale et le propionate de fluticasone (PF) dans une formulation in\u00e9dite administr\u00e9e par un seul dispositif. Il s\u2019agit du premier traitement de la RA \u00e0 franchir le seuil des 5 minutes pour le d\u00e9lai d\u2019action, offrant un soulagement cliniquement pertinent en 15 minutes, soit bien plus rapidement que l\u2019association PF + loratadine orale. Le MP-AzeFlu r\u00e9duit \u00e9galement de mani\u00e8re significative l\u2019hyperr\u00e9activit\u00e9 nasale (HRN), qui peut \u00eatre responsable des sympt\u00f4mes de perc\u00e9e fr\u00e9quemment signal\u00e9s par les patients. Les m\u00e9canismes sous-jacents \u00e0 l\u2019effet du MP-AzeFlu incluent l\u2019inhibition de la d\u00e9granulation des mastocytes, la stabilisation de la barri\u00e8re muqueuse, l\u2019inhibition synergique du recrutement des cellules inflammatoires et une d\u00e9sensibilisation unique des neurones sensoriels exprimant les canaux TRPA1 et TRPV1.        <\/p>\n<p><strong>Co-auteurs :<\/strong> Claus Bachert, Jean Bousquet et Peter Hellings<\/p>\n<p><span class=\"button-ckeditor button-ckeditor--blue\"><a href=\"https:\/\/ctajournal.biomedcentral.com\/articles\/10.1186\/s13601-018-0210-2\" target=\"_blank\" rel=\"noopener\"><strong>Lire l&#8217;article ici<\/strong><\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph photo-gallery paragraph-id--2789 paragraph--type--photo-gallery paragraph--view-mode--default clearfix p-photo-gallery--col\">\n<div class=\"photo-gallery__content\">\n<div class=\"paragraph photo paragraph-id--2786 paragraph--type--photo paragraph--view-mode--default clearfix\">\n<p><a href=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig-1-2.png?itok=5aPuV58_%20\" data-caption=\"Figure 1. Allergic rhinitis (AR) control according to treatment in a single Allergy Diary user. VAS: visual analogue scale; AH: anti-histamine; INS: intranasal corticosteroid; MP-AzeFlu (MP-azelastine\/fluticasone propionate); AR: allergic rhinitis. Reprinted with permission from MACVIA-ARIA  \" data-fancybox=\"images\"><br \/>\n<img decoding=\"async\" src=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig-1.png\"><br \/>\n<\/a><\/p>\n<\/div>\n<div class=\"paragraph photo paragraph-id--2787 paragraph--type--photo paragraph--view-mode--default clearfix\">\n<p><a href=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig.-2_1-1.png?itok=QNQcZUhj%20\" data-caption=\"Figure 2. Effect of MP-AzeFlu, FP + LOR and placebo on nasal symptoms. Data are presented as mean change from baseline in total nasal symptom score (TNSS) assessed over a period of 4 h following exposure to ragweed pollen in an allergen exposure chamber.\" data-fancybox=\"images\"><br \/>\n<img decoding=\"async\" src=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig.-2_1.png\"><br \/>\n<\/a><\/p>\n<\/div>\n<div class=\"paragraph photo paragraph-id--2788 paragraph--type--photo paragraph--view-mode--default clearfix\">\n<p><a href=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig.-3-Effect-of-MP-AzeFlu-on-nasal-hyperreactivity-induced-by-cold-dry-air-provocation-1.png?itok=bTLMsUP2%20\" data-caption=\"  Figure 3. Effect of MP-AzeFlu on nasal-hyperreactivity induced by cold dry air provocation.\" data-fancybox=\"images\"><br \/>\n<img decoding=\"async\" src=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig.-3-Effect-of-MP-AzeFlu-on-nasal-hyperreactivity-induced-by-cold-dry-air-provocation.png\"><br \/>\n<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nouvelles cibles dans la prise en charge de la rhinite allergique La rhinite allergique (RA) reste sous-diagnostiqu\u00e9e, sous-estim\u00e9e et sous-trait\u00e9e. Un \u00e9l\u00e9ment cl\u00e9 pour comprendre le paysage de la RA a \u00e9t\u00e9 la prise de conscience d\u2019un d\u00e9calage important entre la mani\u00e8re dont les m\u00e9decins demandent aux patients de g\u00e9rer leur maladie et ce que ces derniers font dans la vie r\u00e9elle. Les donn\u00e9es de l\u2019Allergy Diary (d\u00e9velopp\u00e9 par MACVIA ARIA) ont montr\u00e9 que les patients souffrant de RA prennent leurs m\u00e9dicaments au besoin, changent rapidement de traitement, pr\u00e9sentent souvent un contr\u00f4le m\u00e9diocre, utilisent des th\u00e9rapies multiples et arr\u00eatent le traitement lorsque les sympt\u00f4mes sont contr\u00f4l\u00e9s. Un meilleur contr\u00f4le de la RA pourrait \u00eatre atteint en utilisant un traitement ayant un d\u00e9lai d\u2019action rapide et ciblant efficacement les sympt\u00f4mes de perc\u00e9e. En effet, les patients citent le soulagement complet des sympt\u00f4mes, l\u2019absence de sympt\u00f4mes de perc\u00e9e, la rapidit\u00e9 d\u2019action, la s\u00e9curit\u00e9 et l\u2019utilisation \u00ab au besoin \u00bb comme cibles cl\u00e9s pour les nouveaux sprays nasaux. Le MP-AzeFlu associe l\u2019az\u00e9lastine intranasale et le propionate de fluticasone (PF) dans une formulation in\u00e9dite administr\u00e9e par un seul dispositif. Il s\u2019agit du premier traitement de la RA \u00e0 franchir le seuil des 5 minutes pour le d\u00e9lai d\u2019action, offrant un soulagement cliniquement pertinent en 15 minutes, soit bien plus rapidement que l\u2019association PF + loratadine orale. Le MP-AzeFlu r\u00e9duit \u00e9galement de mani\u00e8re significative l\u2019hyperr\u00e9activit\u00e9 nasale (HRN), qui peut \u00eatre responsable des sympt\u00f4mes de perc\u00e9e fr\u00e9quemment signal\u00e9s par les patients. Les m\u00e9canismes sous-jacents \u00e0 l\u2019effet du MP-AzeFlu incluent l\u2019inhibition de la d\u00e9granulation des mastocytes, la stabilisation de la barri\u00e8re muqueuse, l\u2019inhibition synergique du recrutement des cellules inflammatoires et une d\u00e9sensibilisation unique des neurones sensoriels exprimant les canaux TRPA1 et TRPV1. Co-auteurs : Claus Bachert, Jean Bousquet et Peter Hellings Lire l&#8217;article ici<\/p>\n","protected":false},"author":1,"featured_media":34549,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[266],"tags":[269,284],"class_list":["post-34531","news","type-news","status-publish","has-post-thumbnail","hentry","category-publications","tag-rhinite-allergique-ra","tag-publications"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale\" \/>\n<meta property=\"og:description\" content=\"Nouvelles cibles dans la prise en charge de la rhinite allergique La rhinite allergique (RA) reste sous-diagnostiqu\u00e9e, sous-estim\u00e9e et sous-trait\u00e9e. Un \u00e9l\u00e9ment cl\u00e9 pour comprendre le paysage de la RA a \u00e9t\u00e9 la prise de conscience d\u2019un d\u00e9calage important entre la mani\u00e8re dont les m\u00e9decins demandent aux patients de g\u00e9rer leur maladie et ce que ces derniers font dans la vie r\u00e9elle. Les donn\u00e9es de l\u2019Allergy Diary (d\u00e9velopp\u00e9 par MACVIA ARIA) ont montr\u00e9 que les patients souffrant de RA prennent leurs m\u00e9dicaments au besoin, changent rapidement de traitement, pr\u00e9sentent souvent un contr\u00f4le m\u00e9diocre, utilisent des th\u00e9rapies multiples et arr\u00eatent le traitement lorsque les sympt\u00f4mes sont contr\u00f4l\u00e9s. Un meilleur contr\u00f4le de la RA pourrait \u00eatre atteint en utilisant un traitement ayant un d\u00e9lai d\u2019action rapide et ciblant efficacement les sympt\u00f4mes de perc\u00e9e. En effet, les patients citent le soulagement complet des sympt\u00f4mes, l\u2019absence de sympt\u00f4mes de perc\u00e9e, la rapidit\u00e9 d\u2019action, la s\u00e9curit\u00e9 et l\u2019utilisation \u00ab au besoin \u00bb comme cibles cl\u00e9s pour les nouveaux sprays nasaux. Le MP-AzeFlu associe l\u2019az\u00e9lastine intranasale et le propionate de fluticasone (PF) dans une formulation in\u00e9dite administr\u00e9e par un seul dispositif. Il s\u2019agit du premier traitement de la RA \u00e0 franchir le seuil des 5 minutes pour le d\u00e9lai d\u2019action, offrant un soulagement cliniquement pertinent en 15 minutes, soit bien plus rapidement que l\u2019association PF + loratadine orale. Le MP-AzeFlu r\u00e9duit \u00e9galement de mani\u00e8re significative l\u2019hyperr\u00e9activit\u00e9 nasale (HRN), qui peut \u00eatre responsable des sympt\u00f4mes de perc\u00e9e fr\u00e9quemment signal\u00e9s par les patients. Les m\u00e9canismes sous-jacents \u00e0 l\u2019effet du MP-AzeFlu incluent l\u2019inhibition de la d\u00e9granulation des mastocytes, la stabilisation de la barri\u00e8re muqueuse, l\u2019inhibition synergique du recrutement des cellules inflammatoires et une d\u00e9sensibilisation unique des neurones sensoriels exprimant les canaux TRPA1 et TRPV1. Co-auteurs : Claus Bachert, Jean Bousquet et Peter Hellings Lire l&#8217;article ici\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/\",\"name\":\"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rapid20Onset20of20Action20and20Reduced20Nasal20Hyperreactivity20Teaser.png\",\"datePublished\":\"2018-06-25T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rapid20Onset20of20Action20and20Reduced20Nasal20Hyperreactivity20Teaser.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rapid20Onset20of20Action20and20Reduced20Nasal20Hyperreactivity20Teaser.png\",\"width\":1748,\"height\":1015},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/","og_locale":"fr_FR","og_type":"article","og_title":"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale","og_description":"Nouvelles cibles dans la prise en charge de la rhinite allergique La rhinite allergique (RA) reste sous-diagnostiqu\u00e9e, sous-estim\u00e9e et sous-trait\u00e9e. Un \u00e9l\u00e9ment cl\u00e9 pour comprendre le paysage de la RA a \u00e9t\u00e9 la prise de conscience d\u2019un d\u00e9calage important entre la mani\u00e8re dont les m\u00e9decins demandent aux patients de g\u00e9rer leur maladie et ce que ces derniers font dans la vie r\u00e9elle. Les donn\u00e9es de l\u2019Allergy Diary (d\u00e9velopp\u00e9 par MACVIA ARIA) ont montr\u00e9 que les patients souffrant de RA prennent leurs m\u00e9dicaments au besoin, changent rapidement de traitement, pr\u00e9sentent souvent un contr\u00f4le m\u00e9diocre, utilisent des th\u00e9rapies multiples et arr\u00eatent le traitement lorsque les sympt\u00f4mes sont contr\u00f4l\u00e9s. Un meilleur contr\u00f4le de la RA pourrait \u00eatre atteint en utilisant un traitement ayant un d\u00e9lai d\u2019action rapide et ciblant efficacement les sympt\u00f4mes de perc\u00e9e. En effet, les patients citent le soulagement complet des sympt\u00f4mes, l\u2019absence de sympt\u00f4mes de perc\u00e9e, la rapidit\u00e9 d\u2019action, la s\u00e9curit\u00e9 et l\u2019utilisation \u00ab au besoin \u00bb comme cibles cl\u00e9s pour les nouveaux sprays nasaux. Le MP-AzeFlu associe l\u2019az\u00e9lastine intranasale et le propionate de fluticasone (PF) dans une formulation in\u00e9dite administr\u00e9e par un seul dispositif. Il s\u2019agit du premier traitement de la RA \u00e0 franchir le seuil des 5 minutes pour le d\u00e9lai d\u2019action, offrant un soulagement cliniquement pertinent en 15 minutes, soit bien plus rapidement que l\u2019association PF + loratadine orale. Le MP-AzeFlu r\u00e9duit \u00e9galement de mani\u00e8re significative l\u2019hyperr\u00e9activit\u00e9 nasale (HRN), qui peut \u00eatre responsable des sympt\u00f4mes de perc\u00e9e fr\u00e9quemment signal\u00e9s par les patients. Les m\u00e9canismes sous-jacents \u00e0 l\u2019effet du MP-AzeFlu incluent l\u2019inhibition de la d\u00e9granulation des mastocytes, la stabilisation de la barri\u00e8re muqueuse, l\u2019inhibition synergique du recrutement des cellules inflammatoires et une d\u00e9sensibilisation unique des neurones sensoriels exprimant les canaux TRPA1 et TRPV1. Co-auteurs : Claus Bachert, Jean Bousquet et Peter Hellings Lire l&#8217;article ici","og_url":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","og_image":[{"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Fig-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/","url":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/","name":"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rapid20Onset20of20Action20and20Reduced20Nasal20Hyperreactivity20Teaser.png","datePublished":"2018-06-25T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rapid20Onset20of20Action20and20Reduced20Nasal20Hyperreactivity20Teaser.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rapid20Onset20of20Action20and20Reduced20Nasal20Hyperreactivity20Teaser.png","width":1748,"height":1015},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/news\/delai-daction-rapide-et-reduction-de-lhyperreactivite-nasale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"D\u00e9lai d\u2019action rapide et r\u00e9duction de l\u2019hyperr\u00e9activit\u00e9 nasale"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/34531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=34531"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/34531\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/34549"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=34531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=34531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=34531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}